<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140907019073N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-10-31</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the efficacy of platelet-enriched plasma injection and laser on knee arthrosis</public_title>
      <acronym></acronym>
      <scientific_title>Comparative Study of The Effectiveness of The Injection of Platelet Rich Plasma with Using High Intensity Laser Therapy Compared with Platelet Rich Plasma and High Intensity Laser Therapy on The Pain, Range of Motion and Function of Patients with Knee Osteoarthritis a single blind randomized control trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-11-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66328</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The block randomization method is used to assign people to the three study groups. For this purpose, the length of the block will be equal to 6 houses (two houses for each treatment). Group A: PRP injection and high-power HILT laser therapy, Group B: PRP injection and placebo laser group, Group C: HILT high-power laser therapy. To assign people to treatments, among the possible choices (number of 15 possible arrangements for blocks), 10 blocks are randomly selected and arranged in one order. Random numbers will be chosen to select 10 blocks out of 15 possible blocks, using R software with a placement-based method by a person who does not know the numbers of the blocks.Patients are assigned to treatments according to the proposed group in the field of selected blocks. This process continues until the end of the samples, Blinding description: In this research, 
-Assessor Clinician: Assessments before and after interventions in the sports medicine assessment clinic will be performed by a sports medicine resident other than the researcher who does not know the presence of patients in the groups.
- Statistical Consultant and Analyzer: The analysis of the research data will be done by a statistical consultant who is not aware of the patient groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Knee Osteoarthritis.</hc_freetext>
      <i_freetext>Intervention 1: First Intervention group:First intervention group: Preparation of PRP solution and injection will be done in sports medicine clinic of Hazrat Rasool Akram Hospital. The patients of both groups are asked to stop taking anticoagulants and aspirin (if used) a week before the injection with the permission of their doctor. To prepare PRP, kits (Arya Mabna Tashkis Corporation, RN: 312569, Rooyagen Kit) are used, which have a completely sterile pack. In order to prepare the injection solution, 35 cc of venous blood from the upper limb is taken from the patients by a 50 cc syringe, which has already drawn 5 cc of anticoagulant solution, and with the help of a blood transfusion adapter with an 18 G needle head and without any pressure on the piston, it is taken into the four A sterile tube is transferred.At the same time, about 0.5 cc of the patient's blood will be sent to the laboratory of Hazrat Rasool Akram Hospital to check the amount of his blood cells. All 4 tubes are filled in a balanced manner and placed inside the centrifuge and rotated at a speed of 1600 RPM for 10 minutes. It is placed and then the tubes are removed.The plasma separated by the first round of centrifugation is drawn into the tubes and poured into two other sterile 10cc tubes inside the box which contain 0.6cc of anti-platelet agent, then put back into the machine and centrifuged at RPM 3500 and It is centrifuged for 6 minutes, then 3cc from the end of both tubes is drawn by a 5cc syringe with a G14 needle after removing the upper plasma.During the injection, the patient is lying supine in a quiet environment and the injected knee is in 45 degrees of flexion. The PRP solution prepared by any one of the methods drawn into the syringe is slowly injected into the knee from the Infero-Medial or Infero-Lateral area with a G21 needle head. After a 30-minute rest under the supervision of a sports medicine specialist, the patient is allowed to leave the clinic using a wheelchair. The second injection will be performed 6 weeks later with the same protocol for these patients.The method of high-intensity laser therapy (HILT) for the first group that receives PRP platelet-enriched plasma injection and high-intensity laser therapy (HILT) will be as follows.The device used in the research is Nd:YAG pulse laser (Physiomed Belgium company). The patient is placed in the Supine open arch position and his affected knee is placed in a 30 degree flexion position (in order to open the joint surface) (the knee angle will be controlled with a goniometer and a towel is placed under the patient's knee to maintain this position) ), then the 6 cm applicator of the device is placed vertically in contact with the joint. Scanning of the joint longitudinal and transverse degrees beyond the internal and external joint line for a duration of 9 minutes with a power of 9 watts (Duty Cycle 70%) frequency 10 Hertz and energy density of 66j/cm2 will be done. Laser therapy will be performed for 6 weeks and 18 sessions (3 sessions per week) for the patients of this group. Intervention 2: Intervention group 2:Intervention group 2: The second group of platelet-enriched plasma (PRP) injection and placebo laser: The platelet-enriched plasma (PRP) injection group will receive a single PRP injection with the same protocol mentioned for the first group. For the placebo laser, with the same protocol mentioned, laser therapy is used for the first group, but with zero output power, which can be achieved by cutting the cable of the laser device. Intervention 3: Intervention group 3: Intervention group 3: The third group of high intensity laser therapy (HILT): for the group of high intensity laser therapy (HILT) with the same device and protocol mentioned for the first group, 12 sessions of laser therapy (3 sessions per week) for 4 weeks. will be done.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Mazaherinezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hazrate-rasool-Hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 6435 2446</telephone>
        <email>mazaherinezhad@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Mazaherinezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hazrate-rasool-Hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 6435 2446</telephone>
        <email>mazaherinezhad@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Grade 2 and 3 of primary knee osteoarthritis acording to KL criteria
Age 50-75 year
Persistent knee pain for at least  6 months with intensity more than 4 according to VAS in activity such as going  up and down stair, long period of sitting and squatting
Ability to walk independently for more than 30 m.
BMI below 35 kg/m2
The patient has full consent to participate in the research.
The patient should have a balanced mental state.</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The patient has a history of intra-articular injection in the knee during the last six months.
The patient has neuromuscular diseases.
The patient has a history of acute traumatic injury to other ligaments and structures of the knee joint with the approval of a specialist.
The patient has a history of surgery or previous injury in the knee and other lower limb joints over the last year.
The patient has bone implants.
The patient has a new fracture in the lower extremities during the last year.
The patient has malignant tumors.
The patient has participated in exercise therapy and physiotherapy programs during the last three months.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First Intervention group:First intervention group: Preparation of PRP solution and injection will be done in sports medicine clinic of Hazrat Rasool Akram Hospital. The patients of both groups are asked to stop taking anticoagulants and aspirin (if used) a week before the injection with the permission of their doctor. To prepare PRP, kits (Arya Mabna Tashkis Corporation, RN: 312569, Rooyagen Kit) are used, which have a completely sterile pack. In order to prepare the injection solution, 35 cc of venous blood from the upper limb is taken from the patients by a 50 cc syringe, which has already drawn 5 cc of anticoagulant solution, and with the help of a blood transfusion adapter with an 18 G needle head and without any pressure on the piston, it is taken into the four A sterile tube is transferred.At the same time, about 0.5 cc of the patient's blood will be sent to the laboratory of Hazrat Rasool Akram Hospital to check the amount of his blood cells. All 4 tubes are filled in a balanced manner and placed inside the centrifuge and rotated at a speed of 1600 RPM for 10 minutes. It is placed and then the tubes are removed.The plasma separated by the first round of centrifugation is drawn into the tubes and poured into two other sterile 10cc tubes inside the box which contain 0.6cc of anti-platelet agent, then put back into the machine and centrifuged at RPM 3500 and It is centrifuged for 6 minutes, then 3cc from the end of both tubes is drawn by a 5cc syringe with a G14 needle after removing the upper plasma.During the injection, the patient is lying supine in a quiet environment and the injected knee is in 45 degrees of flexion. The PRP solution prepared by any one of the methods drawn into the syringe is slowly injected into the knee from the Infero-Medial or Infero-Lateral area with a G21 needle head. After a 30-minute rest under the supervision of a sports medicine specialist, the patient is allowed to leave the clinic using a wheelchair. The second injection will be performed 6 weeks later with the same protocol for these patients.The method of high-intensity laser therapy (HILT) for the first group that receives PRP platelet-enriched plasma injection and high-intensity laser therapy (HILT) will be as follows.The device used in the research is Nd:YAG pulse laser (Physiomed Belgium company). The patient is placed in the Supine open arch position and his affected knee is placed in a 30 degree flexion position (in order to open the joint surface) (the knee angle will be controlled with a goniometer and a towel is placed under the patient's knee to maintain this position) ), then the 6 cm applicator of the device is placed vertically in contact with the joint. Scanning of the joint longitudinal and transverse degrees beyond the internal and external joint line for a duration of 9 minutes with a power of 9 watts (Duty Cycle 70%) frequency 10 Hertz and energy density of 66j/cm2 will be done. Laser therapy will be performed for 6 weeks and 18 sessions (3 sessions per week) for the patients of this group.</i_keyword>
      <i_keyword>Intervention group 2:Intervention group 2: The second group of platelet-enriched plasma (PRP) injection and placebo laser: The platelet-enriched plasma (PRP) injection group will receive a single PRP injection with the same protocol mentioned for the first group. For the placebo laser, with the same protocol mentioned, laser therapy is used for the first group, but with zero output power, which can be achieved by cutting the cable of the laser device.</i_keyword>
      <i_keyword>Intervention group 3: Intervention group 3: The third group of high intensity laser therapy (HILT): for the group of high intensity laser therapy (HILT) with the same device and protocol mentioned for the first group, 12 sessions of laser therapy (3 sessions per week) for 4 weeks. will be done.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Knee function with WOMAC(Western Ontario and McMaster Universities Osteoarthritis Index) scale. Timepoint: Before the intervention and one month and three months after the intervention. Method of measurement: Western Ontario and McMaster Universities Osteoarthritis Index questionnaire.</prim_outcome>
      <prim_outcome>Feeling knee pain by Visual Analogue Scale (VAS). Timepoint: Before the intervention and one month and three months after the intervention. Method of measurement: Visual Analogue Scale (VAS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Knee range of motion. Timepoint: Before the intervention, one month and three months after the intervention. Method of measurement: Goniometry.</sec_outcome>
      <sec_outcome>Timed Up &amp; Go test: The ability of a person to get up from a chair over a distance of 3 meters and return to the chair. Timepoint: Before the intervention, one month and three months after the intervention. Method of measurement: Stopwatch (seconds).</sec_outcome>
      <sec_outcome>Six Minute Walk test: The person's ability to walk for 6 minutes. Timepoint: Before the intervention, one month and three months after the intervention. Method of measurement: Distance measurement (meter).</sec_outcome>
      <sec_outcome>Stair climbing test: The ability of a person to climb stairs to reach the stage of pain or fatigue. Timepoint: Before the intervention, one month and three months after the intervention. Method of measurement: The number of steps taken.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-03</approval_date>
        <contact_name>Research Ethics Committees of School of Medicine</contact_name>
        <contact_address>Rasool-e-Akram Hospital, Niyayesh Ave, Sattarkhan St., Tehran, Iran. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
